Buch, Englisch, 757 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 1326 g
Reihe: Contemporary Neuroscience
From Bench to Clinic
Buch, Englisch, 757 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 1326 g
Reihe: Contemporary Neuroscience
ISBN: 978-1-58829-881-2
Verlag: Humana Press
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Neuropharmakologie, Psychopharmakologie
Weitere Infos & Material
Opioid Receptors.- Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance.- Upregulation of Opioid Receptors.- Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders.- Opioid Receptor Antagonist-Mediated Signaling in the Immune System.- Opioid Antagonists: Chemistry and Pharmacology.- The Chemistry and Pharmacology of ?-Opioid Antagonists.- Medicinal Chemistry of Kappa Opioid Receptor Antagonists.- The Chemistry and Pharmacology of Delta Opioid Antagonists.- Novel Opioid Antagonists with Mixed/Dual Selectivity.- Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists.- Methylnaltrexone: A Peripherally Acting Opioid Antagonist.- Substance Abuse.- Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration.- Naltrexone for Initiation and Maintenance of Opiate Abstinence.- Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids.- Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of ?-Agonist Opiates.- Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine.- Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence.- Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions.- Alcohol and Ingestive Behaviors.- Opioid Antagonists and Ethanol's Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies.- Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence.- Preclinical Effects of Opioid Antagonists on Feeding and Appetite.- CNS Opiate Systems and Eating Disorders.- Behavioral Disorders.- Potential Utility of Kappa Ligands in the Treatment of MoodDisorders.- Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania.- Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior.- Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia.- Medical Indications.- Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug).- Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose.- Kappa-Opioid Antagonists as Pruritogenic Agents.- Clinical Effect of Opioid Antagonists on Clinical Pruritus.- Effects of Opioid Antagonists on l-DOPA-Induced Dyskinesia in Parkinson's Disease.- Endocrine Effects of Opioid Antagonists.- Opioid Antagonists in Traumatic Shock: Animal and Human Studies.- The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats.- A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms.- Nonclinical Pharmacology of VIVITROL®: A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence.- The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence.- The Development of ProNeura Technology for the Treatment of Addictions.- Development of Opioid Transdermal Delivery Systems.- Intranasal Naloxone for Treatment of Opioid Overdose.